NASDAQ:INO

Inovio Pharmaceuticals Competitors

$9.09
+0.36 (+4.12 %)
(As of 04/14/2021 01:21 PM ET)
Add
Compare
Today's Range
$8.71
Now: $9.09
$9.20
50-Day Range
$8.24
MA: $9.84
$12.88
52-Week Range
$6.88
Now: $9.09
$33.79
Volume138,474 shs
Average Volume13.85 million shs
Market Capitalization$1.89 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.08

Competitors

Inovio Pharmaceuticals (NASDAQ:INO) Vs. GMED, INSP, HAE, IART, NARI, and TNDM

Should you be buying INO stock or one of its competitors? Companies in the industry of "surgical & medical instruments" are considered alternatives and competitors to Inovio Pharmaceuticals, including Globus Medical (GMED), Inspire Medical Systems (INSP), Haemonetics (HAE), Integra LifeSciences (IART), Inari Medical (NARI), and Tandem Diabetes Care (TNDM).

Inovio Pharmaceuticals (NASDAQ:INO) and Globus Medical (NYSE:GMED) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.

Profitability

This table compares Inovio Pharmaceuticals and Globus Medical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Inovio Pharmaceuticals-8,518.10%-78.17%-40.33%
Globus Medical12.36%9.85%9.04%

Insider and Institutional Ownership

36.0% of Inovio Pharmaceuticals shares are held by institutional investors. Comparatively, 64.4% of Globus Medical shares are held by institutional investors. 4.0% of Inovio Pharmaceuticals shares are held by company insiders. Comparatively, 25.6% of Globus Medical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Inovio Pharmaceuticals and Globus Medical's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Inovio Pharmaceuticals$4.11 million460.71$-119,360,000.00($1.16)-7.84
Globus Medical$785.37 million8.72$155.21 million$1.6840.83

Globus Medical has higher revenue and earnings than Inovio Pharmaceuticals. Inovio Pharmaceuticals is trading at a lower price-to-earnings ratio than Globus Medical, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Inovio Pharmaceuticals has a beta of 1.08, suggesting that its share price is 8% more volatile than the S&P 500. Comparatively, Globus Medical has a beta of 1.02, suggesting that its share price is 2% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and target prices for Inovio Pharmaceuticals and Globus Medical, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Inovio Pharmaceuticals14302.25
Globus Medical041002.71

Inovio Pharmaceuticals currently has a consensus price target of $17.00, suggesting a potential upside of 87.22%. Globus Medical has a consensus price target of $66.40, suggesting a potential downside of 2.60%. Given Inovio Pharmaceuticals' higher possible upside, equities research analysts clearly believe Inovio Pharmaceuticals is more favorable than Globus Medical.

Summary

Globus Medical beats Inovio Pharmaceuticals on 11 of the 14 factors compared between the two stocks.

Inovio Pharmaceuticals (NASDAQ:INO) and Inspire Medical Systems (NYSE:INSP) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.

Profitability

This table compares Inovio Pharmaceuticals and Inspire Medical Systems' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Inovio Pharmaceuticals-8,518.10%-78.17%-40.33%
Inspire Medical Systems-61.07%-32.23%-26.42%

Insider and Institutional Ownership

36.0% of Inovio Pharmaceuticals shares are held by institutional investors. Comparatively, 96.3% of Inspire Medical Systems shares are held by institutional investors. 4.0% of Inovio Pharmaceuticals shares are held by company insiders. Comparatively, 6.6% of Inspire Medical Systems shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Inovio Pharmaceuticals and Inspire Medical Systems' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Inovio Pharmaceuticals$4.11 million460.71$-119,360,000.00($1.16)-7.84
Inspire Medical Systems$82.05 million74.95$-33,240,000.00($1.40)-161.69

Inspire Medical Systems has higher revenue and earnings than Inovio Pharmaceuticals. Inspire Medical Systems is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Inovio Pharmaceuticals has a beta of 1.08, suggesting that its share price is 8% more volatile than the S&P 500. Comparatively, Inspire Medical Systems has a beta of 1.71, suggesting that its share price is 71% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and target prices for Inovio Pharmaceuticals and Inspire Medical Systems, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Inovio Pharmaceuticals14302.25
Inspire Medical Systems03802.73

Inovio Pharmaceuticals currently has a consensus price target of $17.00, suggesting a potential upside of 87.22%. Inspire Medical Systems has a consensus price target of $168.5455, suggesting a potential downside of 25.33%. Given Inovio Pharmaceuticals' higher possible upside, equities research analysts clearly believe Inovio Pharmaceuticals is more favorable than Inspire Medical Systems.

Summary

Inspire Medical Systems beats Inovio Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

Inovio Pharmaceuticals (NASDAQ:INO) and Haemonetics (NYSE:HAE) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.

Valuation & Earnings

This table compares Inovio Pharmaceuticals and Haemonetics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Inovio Pharmaceuticals$4.11 million460.71$-119,360,000.00($1.16)-7.84
Haemonetics$988.48 million6.03$76.53 million$3.3135.43

Haemonetics has higher revenue and earnings than Inovio Pharmaceuticals. Inovio Pharmaceuticals is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

36.0% of Inovio Pharmaceuticals shares are held by institutional investors. Comparatively, 96.2% of Haemonetics shares are held by institutional investors. 4.0% of Inovio Pharmaceuticals shares are held by company insiders. Comparatively, 1.6% of Haemonetics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and target prices for Inovio Pharmaceuticals and Haemonetics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Inovio Pharmaceuticals14302.25
Haemonetics00403.00

Inovio Pharmaceuticals currently has a consensus price target of $17.00, suggesting a potential upside of 87.22%. Haemonetics has a consensus price target of $144.80, suggesting a potential upside of 23.51%. Given Inovio Pharmaceuticals' higher possible upside, equities research analysts clearly believe Inovio Pharmaceuticals is more favorable than Haemonetics.

Risk and Volatility

Inovio Pharmaceuticals has a beta of 1.08, suggesting that its share price is 8% more volatile than the S&P 500. Comparatively, Haemonetics has a beta of 0.56, suggesting that its share price is 44% less volatile than the S&P 500.

Profitability

This table compares Inovio Pharmaceuticals and Haemonetics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Inovio Pharmaceuticals-8,518.10%-78.17%-40.33%
Haemonetics11.76%22.85%10.40%

Summary

Haemonetics beats Inovio Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

Integra LifeSciences (NASDAQ:IART) and Inovio Pharmaceuticals (NASDAQ:INO) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, dividends, valuation, risk, institutional ownership, analyst recommendations and earnings.

Valuation and Earnings

This table compares Integra LifeSciences and Inovio Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Integra LifeSciences$1.52 billion3.93$50.20 million$2.7425.77
Inovio Pharmaceuticals$4.11 million460.71$-119,360,000.00($1.16)-7.84

Integra LifeSciences has higher revenue and earnings than Inovio Pharmaceuticals. Inovio Pharmaceuticals is trading at a lower price-to-earnings ratio than Integra LifeSciences, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

85.7% of Integra LifeSciences shares are held by institutional investors. Comparatively, 36.0% of Inovio Pharmaceuticals shares are held by institutional investors. 4.3% of Integra LifeSciences shares are held by insiders. Comparatively, 4.0% of Inovio Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Integra LifeSciences and Inovio Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Integra LifeSciences14402.33
Inovio Pharmaceuticals14302.25

Integra LifeSciences presently has a consensus price target of $67.8889, suggesting a potential downside of 3.72%. Inovio Pharmaceuticals has a consensus price target of $17.00, suggesting a potential upside of 87.22%. Given Inovio Pharmaceuticals' higher probable upside, analysts plainly believe Inovio Pharmaceuticals is more favorable than Integra LifeSciences.

Volatility & Risk

Integra LifeSciences has a beta of 1.26, meaning that its share price is 26% more volatile than the S&P 500. Comparatively, Inovio Pharmaceuticals has a beta of 1.08, meaning that its share price is 8% more volatile than the S&P 500.

Profitability

This table compares Integra LifeSciences and Inovio Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Integra LifeSciences4.10%14.26%5.77%
Inovio Pharmaceuticals-8,518.10%-78.17%-40.33%

Summary

Integra LifeSciences beats Inovio Pharmaceuticals on 12 of the 14 factors compared between the two stocks.

Inari Medical (NASDAQ:NARI) and Inovio Pharmaceuticals (NASDAQ:INO) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, dividends, valuation, risk, institutional ownership, analyst recommendations and earnings.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Inari Medical and Inovio Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Inari Medical01502.83
Inovio Pharmaceuticals14302.25

Inari Medical presently has a consensus price target of $116.1667, suggesting a potential upside of 3.51%. Inovio Pharmaceuticals has a consensus price target of $17.00, suggesting a potential upside of 87.22%. Given Inovio Pharmaceuticals' higher probable upside, analysts plainly believe Inovio Pharmaceuticals is more favorable than Inari Medical.

Profitability

This table compares Inari Medical and Inovio Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Inari MedicalN/AN/AN/A
Inovio Pharmaceuticals-8,518.10%-78.17%-40.33%

Valuation and Earnings

This table compares Inari Medical and Inovio Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Inari MedicalN/AN/AN/AN/AN/A
Inovio Pharmaceuticals$4.11 million460.71$-119,360,000.00($1.16)-7.84

Inari Medical has higher earnings, but lower revenue than Inovio Pharmaceuticals.

Institutional and Insider Ownership

17.8% of Inari Medical shares are held by institutional investors. Comparatively, 36.0% of Inovio Pharmaceuticals shares are held by institutional investors. 4.0% of Inovio Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Inari Medical beats Inovio Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

Inovio Pharmaceuticals (NASDAQ:INO) and Tandem Diabetes Care (NASDAQ:TNDM) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability and earnings.

Analyst Ratings

This is a summary of current ratings and recommmendations for Inovio Pharmaceuticals and Tandem Diabetes Care, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Inovio Pharmaceuticals14302.25
Tandem Diabetes Care04902.69

Inovio Pharmaceuticals presently has a consensus target price of $17.00, suggesting a potential upside of 87.22%. Tandem Diabetes Care has a consensus target price of $115.9231, suggesting a potential upside of 33.71%. Given Inovio Pharmaceuticals' higher probable upside, equities research analysts plainly believe Inovio Pharmaceuticals is more favorable than Tandem Diabetes Care.

Profitability

This table compares Inovio Pharmaceuticals and Tandem Diabetes Care's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Inovio Pharmaceuticals-8,518.10%-78.17%-40.33%
Tandem Diabetes Care-11.10%-10.98%-5.59%

Valuation & Earnings

This table compares Inovio Pharmaceuticals and Tandem Diabetes Care's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Inovio Pharmaceuticals$4.11 million460.71$-119,360,000.00($1.16)-7.84
Tandem Diabetes Care$362.30 million14.95$-24,750,000.00($0.22)-394.00

Tandem Diabetes Care has higher revenue and earnings than Inovio Pharmaceuticals. Tandem Diabetes Care is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Inovio Pharmaceuticals has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500. Comparatively, Tandem Diabetes Care has a beta of 0.31, meaning that its stock price is 69% less volatile than the S&P 500.

Institutional & Insider Ownership

36.0% of Inovio Pharmaceuticals shares are held by institutional investors. Comparatively, 88.6% of Tandem Diabetes Care shares are held by institutional investors. 4.0% of Inovio Pharmaceuticals shares are held by insiders. Comparatively, 6.0% of Tandem Diabetes Care shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Tandem Diabetes Care beats Inovio Pharmaceuticals on 10 of the 14 factors compared between the two stocks.


Inovio Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Globus Medical logo
GMED
Globus Medical
1.4$68.59+1.4%$6.75 billion$785.37 million74.55
Inspire Medical Systems logo
INSP
Inspire Medical Systems
1.2$226.36+2.3%$6.01 billion$82.05 million-97.57
Haemonetics logo
HAE
Haemonetics
1.6$117.28+0.2%$5.97 billion$988.48 million56.66
Integra LifeSciences logo
IART
Integra LifeSciences
1.4$70.60+1.0%$5.90 billion$1.52 billion105.37Insider Selling
Inari Medical logo
NARI
Inari Medical
1.1$112.23+1.5%$5.55 billionN/A0.00Insider Selling
Tandem Diabetes Care logo
TNDM
Tandem Diabetes Care
1.6$86.68+1.5%$5.50 billion$362.30 million-107.01
Nevro logo
NVRO
Nevro
1.2$149.76+2.4%$5.06 billion$390.26 million-55.06News Coverage
ShockWave Medical logo
SWAV
ShockWave Medical
1.2$142.75+0.9%$4.93 billion$42.93 million-70.67
ICU Medical logo
ICUI
ICU Medical
1.5$208.04+1.0%$4.37 billion$1.27 billion55.04Insider Selling
Glaukos logo
GKOS
Glaukos
0.9$84.91+2.3%$3.80 billion$236.98 million-51.46Analyst Upgrade
Analyst Revision
Cantel Medical logo
CMD
Cantel Medical
1.3$85.49+0.6%$3.59 billion$1.02 billion101.78
NuVasive logo
NUVA
NuVasive
1.1$69.29+1.2%$3.52 billion$1.17 billion-314.95
Merit Medical Systems logo
MMSI
Merit Medical Systems
1.5$61.82+1.4%$3.39 billion$994.85 million-116.64
AtriCure logo
ATRC
AtriCure
1.5$66.75+1.2%$3.01 billion$230.81 million-58.04Analyst Report
iRhythm Technologies logo
IRTC
iRhythm Technologies
1.5$92.08+6.9%$2.50 billion$214.55 million-48.21Analyst Report
Unusual Options Activity
Analyst Revision
News Coverage
Axonics Modulation Technologies logo
AXNX
Axonics Modulation Technologies
1.3$59.35+1.4%$2.43 billion$13.82 million-30.28
GenMark Diagnostics logo
GNMK
GenMark Diagnostics
1.5$23.99+0.0%$1.75 billion$88.02 million-58.51Increase in Short Interest
Luminex logo
LMNX
Luminex
1.5$36.85+0.3%$1.75 billion$334.64 million94.49Analyst Upgrade
Unusual Options Activity
News Coverage
Silk Road Medical logo
SILK
Silk Road Medical
1.1$51.19+2.3%$1.72 billion$63.35 million-41.96
Alphatec logo
ATEC
Alphatec
0.8$17.32+1.1%$1.63 billion$113.43 million-15.75Insider Selling
Pulmonx logo
LUNG
Pulmonx
1.4$43.73+2.9%$1.61 billion$32.60 million0.00Increase in Short Interest
Cardiovascular Systems logo
CSII
Cardiovascular Systems
1.7$37.69+3.1%$1.47 billion$236.54 million-57.11
MiMedx Group logo
MDXG
MiMedx Group
1.7$12.24+1.3%$1.38 billion$299.26 million-13.02
Atrion logo
ATRI
Atrion
1.1$648.60+0.5%$1.18 billion$155.07 million36.54
Tactile Systems Technology logo
TCMD
Tactile Systems Technology
1.2$56.64+2.4%$1.08 billion$189.49 million-125.86
SI-BONE logo
SIBN
SI-BONE
1.2$33.21+0.7%$1.08 billion$67.30 million-20.76Increase in Short Interest
Cerus logo
CERS
Cerus
1.5$6.33+1.1%$1.05 billion$74.65 million-16.23News Coverage
LeMaitre Vascular logo
LMAT
LeMaitre Vascular
1.9$49.69+0.6%$1.03 billion$117.23 million53.43
OrthoPediatrics logo
KIDS
OrthoPediatrics
1.5$49.47+0.8%$964.42 million$72.55 million-34.35
AngioDynamics logo
ANGO
AngioDynamics
1.4$24.01+0.1%$916.43 million$264.16 million-5.37Decrease in Short Interest
CryoLife logo
CRY
CryoLife
1.8$22.66+0.5%$891.15 million$276.22 million-59.63
Orthofix Medical logo
OFIX
Orthofix Medical
1.2$43.20+0.6%$847.99 million$459.95 million36.00
Surmodics logo
SRDX
Surmodics
1.3$57.02+0.8%$790.83 million$94.86 million712.75
OraSure Technologies logo
OSUR
OraSure Technologies
1.7$10.31+0.1%$742.48 million$154.60 million-44.83
Antares Pharma logo
ATRS
Antares Pharma
1.8$4.05+0.2%$679.37 million$123.86 million67.51
Intersect ENT logo
XENT
Intersect ENT
1.4$19.94+1.0%$652.07 million$109.14 million-10.44
Vapotherm logo
VAPO
Vapotherm
1.5$22.88+0.9%$595.63 million$48.10 million-10.90
SeaSpine logo
SPNE
SeaSpine
1.3$21.57+2.1%$589.95 million$159.08 million-12.92Analyst Upgrade
Anika Therapeutics logo
ANIK
Anika Therapeutics
1.5$41.03+1.5%$579.22 million$114.51 million-87.30Gap Down
Pulse Biosciences logo
PLSE
Pulse Biosciences
1.5$21.96+2.8%$556.70 millionN/A-9.67
Accuray logo
ARAY
Accuray
2.3$5.26+0.8%$484.93 million$382.93 million37.57News Coverage
iCAD logo
ICAD
iCAD
1.5$18.66+3.0%$451.02 million$31.34 million-19.64
AVITA Medical logo
RCEL
AVITA Medical
1.5$20.88+0.6%$449.02 million$14.26 million-10.09Analyst Report
Increase in Short Interest
ClearPoint Neuro logo
CLPT
ClearPoint Neuro
1.4$20.98+4.1%$415.73 million$11.22 million-47.68News Coverage
Profound Medical logo
PROF
Profound Medical
1.6$20.20+1.2%$414.73 million$4.17 million-17.26News Coverage
Cytosorbents logo
CTSO
Cytosorbents
1.7$9.09+1.8%$400.19 million$24.95 million-27.55
PAVmed logo
PAVM
PAVmed
1.4$5.03+5.4%$392.51 millionN/A-6.62Gap Down
UFP Technologies logo
UFPT
UFP Technologies
1.3$49.50+0.4%$370.59 million$198.38 million24.75
Acutus Medical logo
AFIB
Acutus Medical
1.3$13.34+1.3%$370.01 million$2.84 million0.00News Coverage
Soliton logo
SOLY
Soliton
1.1$17.62+5.6%$352.56 millionN/A-23.49
This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.